Immunomodulation of Selective Naive T Cell Functions by p110δ Inactivation Improves the Outcome of Mismatched Cell Transplantation  by Doisne, Jean-Marc et al.
ArticleImmunomodulation of Selective Naive T Cell
Functions by p110d Inactivation Improves the
Outcome of Mismatched Cell TransplantationGraphical AbstractHighlightsd Genetic p110d inactivation in donor naive T cells mitigates
GvHD in mice
d Pharmacological p110d inactivation in human T cells reduces
alloreactivityDoisne et al., 2015, Cell Reports 10, 702–710
February 10, 2015 ª2015 The Authors
http://dx.doi.org/10.1016/j.celrep.2015.01.002Authors
Jean-Marc Doisne, Christian M. Hu¨ber,




Using amousemodel of fully mismatched
hematopoietic cell transplantation,
Doisne et al. show that p110d inactivation
interferes with selective naive T cell
functions and favorably sways the
balance between graft versus leukemia
and graft versus host disease.
Furthermore, inactivation of p110d in
human lymphocytes reduces T cell
allorecognition.
Cell Reports
ArticleImmunomodulation of Selective Naive T Cell
Functions by p110d Inactivation Improves
the Outcome of Mismatched Cell Transplantation
Jean-Marc Doisne,1,* Christian M. Hu¨ber,1 Klaus Okkenhaug,2 and Francesco Colucci1
1Department of Obstetrics and Gynaecology, University of Cambridge School of Clinical Medicine, NIHR Cambridge Biomedical Research
Centre, Cambridge CB2 0SW, UK
2Laboratory for Lymphocyte Signaling and Development, Babraham Research Campus, The Babraham Institute, Cambridge CB22 3AT, UK
*Correspondence: jmd83@medschl.cam.ac.uk
http://dx.doi.org/10.1016/j.celrep.2015.01.002
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/3.0/).SUMMARY
Allogeneic hematopoietic stem cell transplantation
(HSCT) can treat certain hematologic malignancies
due to the graft versus leukemia (GvL) effect but is
complicated by graft versus host disease (GvHD).
Expression of the p110d catalytic subunit of the phos-
phoinositide 3-kinase pathway is restricted to leuko-
cytes, where it regulates proliferation, migration,
and cytokine production. Here, in a mouse model of
fully mismatched hematopoietic cell transplantation
(HCT), we show that genetic inactivation of p110d in
T cells leads to milder GvHD, whereas GvL is pre-
served. Inactivation of p110d in human lymphocytes
reduced T cell allorecognition. We demonstrate that
both allostimulation and granzyme B expression
were dependent on p110d in naive T cells, which are
the main mediators of GvHD, whereas memory
T cells were unaffected. Strikingly, p110d is not
mandatory for either naive or memory T cells to
mediate GvL. Therefore, immunomodulation of selec-
tive naive T cell functions by p110d inactivation im-
proves the outcome of allogeneic HSCT.
INTRODUCTION
Allogeneic hematopoietic stem cell transplantation (HSCT) is a
challenging procedure used to treat certain malignancies. The
challenge is to minimize the complications and maximize the
benefits of the genetic disparity between donors and recipients.
Mismatched T cells in the graft provide alloreactivity against
cancer cells (graft versus leukemia [GvL]); however, mismatched
T cells also react against host tissue antigens, leading to graft
versus host disease (GvHD). The devastating effects of GvHD
are limited by immunosuppressive treatment of patients, but
current regimens increase the risk of relapse and opportunistic
infections. Combination therapies that harness the power of im-
mune cells and the potential of newdrugs tomanipulate selective
lymphocyte functions (Houot et al., 2011; McDaniel et al., 2012)
may be considered to improve the outcome of allogeneic702 Cell Reports 10, 702–710, February 10, 2015 ª2015 The AuthorsHSCT (Li and Sykes, 2012), and recent work suggests that inter-
fering with proximal T cell signaling may be an effective strategy
(Valenzuela et al., 2009; Haarberg et al., 2013). In mice, naive
T cells mediate both GvL and GvHD, whereas memory T cells
mediate only GvL (Dutt et al., 2011; Ruggeri et al., 2002); thus,
small-molecule inhibitors that target selective functions in naive
T cells may improve the outcome of allogeneic HSCT.
Phosphoinositide 3-kinase (PI3K) enzymes are crucial compo-
nents of lymphocyte development and function (Okkenhaug,
2013). The catalytic subunits p110g and p110d are predomi-
nantly expressed in hematopoietic cells (HCs). It has been shown
that p110d is important for development, differentiation, and
regulation of T cell subsets (Patton et al., 2007; Okkenhaug,
2013). Emerging evidence suggests that p110d is an attractive
pharmacological target to modulate both unwanted immune re-
sponses and certain blood cancers (Soond et al., 2010; Billottet
et al., 2006; Sujobert et al., 2005). Indeed, p110d-selective inhib-
itors are currently being tested in clinical trials to treat autoimmu-
nity, allergy, and lymphoid malignancies. For example, idelalisib
(GS-1101, CAL-101), which is derived from IC87114, is being
tested for treating non-Hodgkin’s lymphoma, Hodgkin’s lym-
phoma, and chronic lymphoid leukemia (Furman et al., 2014).
Our results show that p110d inactivation interferes with selec-
tive naive T cell functions and favorably sways the balance be-
tween GvL and GvHD during the course of allogeneic HSCT.
RESULTS
Alleviated GvHD
Mouse models of acute GvHD show different levels of severity,
depending on the number and timing of allogeneic cell injection
and whether total splenocytes or only T cell subsets are injected.
We set up a mouse model of fully mismatched HSCT (B6 into
BALB/c mice), in which purified T cells are injected soon after le-
thal irradiation and cause acute severe GvHD and death of recip-
ient mice within 7 days.
To assess the impact of p110d inactivation on T cells in GvHD,
we used transgenic (p110dD910A) knockin mice, which carry a
loss-of-function point mutation in the kinase domain of p110d
(Okkenhaug et al., 2002). We lethally irradiated BALB/c mice,
in which we then transferred myeloprotective cells from T cell
depleted (TCD) B6 bone marrow cells (BMCs) alone (BM group)
Figure 1. Inactivation of p110d Reduces GvHD Severity and Impairs Allogeneic T Cell Functions In Vivo
(A) Survival curve of two combined independent experiments where lethally irradiated BALB/c hosts were intravenously (i.v.) injected with either 5 3 106 TCD-
BMCs only (BM group, n = 10) or 5 3 106 TCD-BMCs and 1 3 106 control T cells (WT T group, n = 10) or 1 3 106 D910A T cells (D910A T group, n = 10). The
difference in survival between the two latter groups is significant (p = 0.02; Mantel-Cox test). The graph on the right panel shows the combined results of two
independent experiments quantifying GvHD clinical score of BALB/c mice receiving p110dWT/D910A (control) T cells (gray column; n = 10) or D910A T cells (white
column; n = 7) evaluated at the endpoint (loss of 20% bodyweight) (mean ± range, unpaired t test).
(B) Spleens from lethally irradiated BALB/cmice injected with allogeneic T cells fromWT (WT T group) or D910A (D910A T group) mice were harvested at day 3, 4,
and 5. Absolute numbers of donor T cells were calculated on the basis of flow cytometry analysis (n = 3–5; mean ± range; unpaired t test; *p = 0.029, ***p = 0.001).
(C) Representative dot plots of CD4+ and CD8+ T cell differentiation profile based on CD62L and CD44 expression 4 days after hematopoietic cell transplantation
(HCT).
(D) At day 5, allogeneic CD8+ T cells from WT (solid line) or D910A (dotted line) mice were analyzed for GzmB expression by flow cytometry. Data are from one
experiment with n = 5 mice in each group (mean ± range, unpaired t test).
(E) The percentage of CD4+ (left) and CD8+ (right) Tregs were assessed at day 5 post-HCT based on the expression of FoxP3 measured by intracellular flow
cytometry (n = 5; mean ± range; unpaired t test).or along with allogeneic T cells from B6 wild-type (WT) (WT T
group) or B6 p110dD910A (D910A T group) mice (Figure 1A).
Most (nine out of ten) mice in the BM group recovered fully
from irradiation and survived until the endpoint (35 days). All
mice in theWT T group had to be culledwithin 6 days after having
rapidly developed clinical signs of severe GvHD reaching the
20% weight loss endpoint and a clinical score of 7 on a scale
of 8 (Figure 1A). In the D910A T group, seven out of ten mice
developed a milder form of GvHD (clinical score 4) but had to
be culled because the weight loss had reached 20%. Remark-
ably, three out of ten mice in this group did recover and survived
for more than 35 days (Figure 1A). Thus, inactivation of p110d
alleviates clinical signs and improves survival in a mouse model
of acute and severe GvHD.
Analysis of host spleens within 5 days posttransplantation re-
vealed 3- to 6-fold fewer donor T cells in mice from the D910A T
group (0.16 ± 0.063 106 at day 4 and 1.05 ± 0.343 106 at day 5)
as compared to the WT T group (1.01 ± 0.37 3 106 at day 4 and
2.99 ± 0.80 3 106 at day 5) (Figure 1B). Furthermore, donor
T cells in the D910A T group containedmore CD62L+CD44hi cen-
tral memory T cells and fewer CD62LCD44hi effector memory
T cells compared to the WT T group (Figure 1C). Cleavage of
CD62L upon allorecognition was inhibited by p110d inactivation,Ceas expected from previous work (Sinclair et al., 2008). Granzyme
B (GzmB) is a key effector molecule in allogeneic CD8+ T cells.
Fewer GzmB+ cells were found within p110dD910A allogeneic
CD8+ T cells (43% ± 5% versus 78% ± 5%), and the cells ex-
pressing GzmB did so at lower intensity (Figure 1D).
Regulatory T cells (Tregs) modulate GvHD and GvL (Hoffmann
et al., 2002; Edinger et al., 2003). PI3K signaling plays a role in
Treg generation and function (Soond et al., 2012). We reasoned
that p110d-inactivated T cells could contain more Tregs, there-
fore explaining the reduced GvHD. We found instead that mice
receiving T cells from B6 p110dD910A mice had 3-fold fewer
CD4+ and CD8+ Tregs (1.5% ± 0.1% versus 4.8% ± 1% and
1% ± 0.09% versus 2.9% ± 0.6%, respectively; Figure 1E), the
latter being generated specifically during allogeneic HSCT in
mice (Robb et al., 2012). These results suggest that the beneficial
effect of p110d inactivation on GvHD is unlikely to be mediated
by Tregs. We therefore reasoned that p110d inactivation may
rather inhibit expansion, differentiation, and acquisition of
effector functions in allogeneic effector T cells.
Preserved GvL
The main reason to transplant mismatched T cells is that they
mediate killing of tumor cells, and we therefore assessed thell Reports 10, 702–710, February 10, 2015 ª2015 The Authors 703
Figure 2. Inactivation of p110d Preserves GvL
Lethally irradiated BALB/c hosts were i.v. injected with 5 3 106 TCD-BMCs
and 53 104 A20 (lymphoma) cells (A20 group, n = 12), 53 106 TCD-BMCs plus
5 3 104 A20 cells in the presence of B6 T cells from either WT (WT T group,
n = 12) or D910A (D910A T group, n = 9) mice. The endpoint for this experiment
was 25%weight loss, rather than 20% as in Figure 1. The p value (Mantel-Cox
test) indicates statistical difference between the WT T group and the D910A T
group. Data are from two experiments with n = 4–8 mice in each group.impact of p110d-inactivation on GvL. We lethally irradiated three
groups of BALB/c mice, in which we then cotransferred myelo-
protective cells (as in the previous experiment) and syngeneic
A20 lymphoma cells alone (A20 group) or along with allogeneic
T cells from B6 WT (WT T group) or B6 p110dD910A (D910A T
group) mice (Figure 2). Instead of culling recipient mice at 20%
of bodyweight loss (Figure 1), we decided to set the endpoint at
25% weight loss. This was because we noticed that mice
receiving p110d-inactivated T cells showed a lower GvHD clinical
score and that the survivingmice regainedweight quickly and sur-
vived in apparent good health. This suggests that the beneficial
effect of p110d inactivation in allogeneic T cells may be delayed.
All mice in the A20 group succumbed to lymphoma within
17 days, and 11 out of 12 mice in the WT T group developed
acute GvHD caused by WT T cells and succumbed within just
1 week. In striking contrast, eight out of nine mice in the D910A
T group recovered after an initial weight loss and survived both
mild GvHD caused by p110d-inactivated T cells (thus confirming
and expanding the results of the previous experiment) and tumor
growth up until day 30 posttransplant, when they were culled for
analysis (Figure 2). No or very few residual lymphoma cells were
found in the spleen, liver, and bone marrow of the eight surviving
mice in theD910Agroup (data not shown), showing that selective
p110d inactivation not only alleviates GvHD but also preserves
robust GvL. On aggregate, these results show that p110d inacti-
vation in donor lymphocytes separates harmful GvHD frombene-
ficial GvL.
Reduced Alloreactivity of Naive T Cells In Vitro
Both naive and memory T cells mediate GvL, but GvHD is medi-
ated by naive T cells only (Dutt et al., 2011). We hypothesized
that the mechanisms underlying the effects of p110d inactivation
on GvHD and GvL could be related to differential requirements
for p110d signaling in naive and memory T cells. To test this hy-
pothesis, we analyzed the effect of selective pharmacological
inhibition of p110d by IC87114 (IC) or idelalisib on naive
(CD62L+CD44lo) and memory (CD44hi) WT T cells in vitro. Phar-
macological inactivation of p110d reduced proliferation of naive704 Cell Reports 10, 702–710, February 10, 2015 ª2015 The AuthorsCD8+ T cells, which underwent one round of division less than
when incubated with the vehicle (seven rather than eight divi-
sions). In contrast, memory CD8+ T cell proliferation was not in-
hibited by pharmacological inactivation of p110d (Figures 3A and
S1A). The pan-PI3K inhibitor LY294002 (LY) strongly reduced
proliferation of both subsets (Figures 3A and S1A). Alloreactive
naive CD8+ T cells displayed a similar CD62L+CD44hi profile
that was also observed in vivo in transgenic cells (Figure 1C),
supporting the notion that p110d inactivation—genetically or
pharmacologically—interferes with differentiation of alloreactive
naive T cells (Figure 3B).
In order to assess the significance of these results in a tractable
cellular model relevant to HSCT, we measured the effects
of pharmacological p110d inactivation in T cell responses to
tumor-primed allogeneic bone marrow-derived dendritic cells
(BMDCs). Naive T cells were more responsive to allogeneic cells
thanmemory T cells, but p110d inactivation halved the number of
alloreactive naive T cells and compromised their differentiation,
whereas memory T cells were unaffected by p110d inactivation
using IC or idelalisib (Figures 3C and S1B). GzmB expression
was strongly suppressed by p110d inactivation in naı¨ve, but not
memory, T cells (Figure 3D). Consistent with reduced PI3K
signaling in naive T cells, but not memory T cells, we found that
p110d inactivation reduced the phosphorylation of Akt at both
sites S473 and T308 in naı¨ve, but not memory, T cells (Figures
3E and S1C). When primed T cells were restimulated with A20
cells or A20-pulsed BMDCs, memory T cells produced more
interferon-g (IFN-g) than naive T cells. Moreover, upon p110d
inactivation during restimulation, only in memory T cells was
IFN-g production enhanced (Figure 3F). Thus, alloreactive naive
and memory T cells have different p110d signaling requirements.
Reduced Alloreactivity of Naive T Cells In Vivo
To confirm our hypothesis, allogeneic naive and memory T cells
were sorted and used as effector cells in our mouse model of se-
vere GvHD. We lethally irradiated five groups of BALB/c mice, in
whichwe then cotransferredmyeloprotective cells and syngeneic
A20 lymphoma cells alone (A20 group) or along with either alloge-
neic naive (WT Tn group) or memory (WT Tm group) T cells from
B6 WT or along with either allogeneic naive (D910A Tn group) or
memory (D910A Tm group) T cells from B6 p110dD910A (Figure 4).
In unseparated T cells, naive T cells are the vast majority (85%).
We injected 1 3 106 purified naive T cells. Rather than injecting
0.15 3 106 cells, which is the number of memory T cells one
should inject to recapitulate the Tn/Tm ratio of unseparated
T cells, we opted for injecting an excess of memory T cells (0.5
3 106 cells; that is, more than three times greater than the Tm
equivalent of unseparated cells), in order to exclude any effect
due to disparity of cell numbers.
The majority of the mice (12/14) in the WT Tn group had to be
culled within 7 days because of GvHD. Among the two remaining
mice, one was culled due to signs of severe late GvHD (weight
loss, skin rush). All mice in the D910A Tn group developedmilder
GvHD and survived longer, demonstrating that allogeneic naive
T cells are less potent inducers of severeGvHDwhen p110d is in-
activated. Some other mice (5/12) developed clinical signs of late
GvHD (skin rush, diarrhea) and had to be culled in accordance
with the UK Home Office regulation. None of the mice in the
Figure 3. Inactivation of p110d Inhibits Allogeneic Naive T Cell Proliferation and Differentiation In Vitro
(A and B) B6 sorted naive and memory T cells were labeled with CFSE and cocultured with LPS-matured and irradiated BALB/c BMDCs at a 1:1 ratio with DMSO
vehicle control or the indicated doses of IC87114 (IC) or LY294002 (LY). At day 5, proliferation (A) and differentiation (B) of CD8+ T cells were quantified. Dif-
ferentiation phenotype is based on CD62L and CD44 expression as follows: naive (Tn; CD62L+CD44lo), central memory-like (Tcm; CD62L+CD44hi), and effector
memory-like (Tem; CD62LCD44hi). Results are representative of three independent experiments.
(C–F) T cells come from the cultured alloreactive T cells generated in vitro in presence of DMSO or IC. These cells were stimulated first with irradiated BALB/c
BMDCs loaded with A20 lysate for 5 days, then expanded with anti-CD3 and anti-CD28 + rmIL-2/rmIL-7 for 2 days and maintained in a low dose of rmIL-2 and
rmIL-7 in the presence of DMSO or IC during the whole process. The level of GzmB (D) and P-Akt (E) were assessed at the end of this process. (C) After 5 days of
priming, Tn and memory (Tm, CD44hi) T cell absolute numbers were evaluated. Tn/Tm ratios were calculated either in DMSO or in IC (5 mM) (left), and DMSO/IC
ratios were determined for each subset (right). Results are from four independent experiments (mean ± range, paired t test). (D) GzmB expressionwas assessed in
Tn and in Tm primed and expanded in the presence of DMSO (solid line) or IC (dotted line). Results are representative of three independent experiments. (E) Tn
and Tm cultured in the presence of DMSO (solid line) or IC (dotted line) were stained for P-Akt (Ser473) or P-Akt (Thr308) and analyzed by flow cytometry. Results
are representative of two independent experiments. (F) Tn (top) or Tm (bottom) cultured in the presence of DMSO (solid line) or IC (dotted line) were stimulated for
5 hr with A20 cells (left) or A20-pulsed BALB/c BMDCs (right). Intracellular IFN-g was stained and analyzed by flow cytometry. The percentages and geometric
mean fluorescence intensities (GMFIs) of IFN-g+ cells are depicted on each histogram. Data are representative of two independent experiments.
See also Figure S1.
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Figure 4. Inactivation of p110d Inhibits Allogeneic Naive T Cells In Vivo
Lethally irradiated BALB/c hosts were i.v. injected with 53 106 TCD-BMCs and 53 104 A20 (lymphoma) cells (A20 group, n = 9), 53 106 TCD-BMCs plus 53 104
A20 cells in the presence of B6 naive T cells (13 106 cells) from either WT (WT Tn group, n = 14) or D910A (D910A Tn group, n = 12) mice, or in the presence of B6
memory T cells (0.53 106 cells) from either WT (WT Tm group, n = 6) or D910A (D910A Tm group, n = 5). The table summarizes the cause of death for each group:
acute GvHD (%7 days), delayed GvHD (>7 days), tumor (<21 days), or delayed tumor (>21 days). The last column shows the overall survival rate at day 91. The
endpoint for this experiment was 25%weight loss. The p values (Mantel-Cox test) compare theWT Tn group with the D910A Tn group and theWT Tm group with
the D910A Tm group. Data are from two experiments with n = 5–14 mice in each group. See also Figure S2.WT Tm group (six out of six) or the D910A Tm group (five out of
five) showed any clinical signs of acute or late GvHD. These re-
sults confirm that allogeneic memory T cells are unable to induce
GvHD, even if the number of memory T cells injected was 3-fold
greater than the equivalent of unseparated Tm/Tn cells.
All mice in the A20 group (nine out of nine, no allogeneic T cell
grafted) died of lymphoma within 19 days. The GvL effect was
observed in the WT Tn group (two remaining mice) and in most
of the mice (9/12) of the D910A Tn group, demonstrating that
naive T cells lacking functional p110d are able to mediate GvL.
Memory T cells are known to mediate GvL (Dutt et al., 2011).
Effectively, a GvL effect could be observed in mice that had
received eitherWT or D910A Tm cells. We noticed a trend for de-
layed lymphoma development in the D910A Tm group, suggest-
ing a stronger GvL effect (Figure 4). Thus, GvL mediated by
p110d-inactive memory T cells may be more robust. Allogeneic
memory T cells upon restimulation produced more IFN-g when
p110d was inactivated (Figure 3F). This is in line with a report
that IFN-g promotes GvL (Yang et al., 2011) and may explain
the more efficient GvL response mediated by p110d inactivation
in memory T cells.
Finally, analysis of the surviving mice after 91 days revealed
complete clearance of A20 lymphoma cells in the BM and in
the spleen, confirming successful GvL response (Figure S2A).
Reconstitution and persistence of engrafted donor HCs oc-
curred in all groups in the BM and in the spleen (Figure S2B
and not shown).
These results demonstrate that naive T cells require p110d
in vivo to cause GvHD, but not to mediate GvL. Moreover, mem-
ory T cells do not cause GvHD and mediate a more potent GvL
when p110d is inactivated. Tumors are cleared in surviving
mice, and the hematopoietic compartment appears to develop
normally.
Reduced Alloreactivity in Human T Cells
To validate the results obtained in murine cells, we assessed the
impact of p110d inactivation in human T cell allorecognition in an
adapted mixed lymphocyte reaction (MLR) assay using HCs706 Cell Reports 10, 702–710, February 10, 2015 ª2015 The Authorsfrom the blood of healthy donors in the presence of either LY
or IC (Figure 5A). The pan-PI3K inhibitor LY reduced the T cell al-
loresponse by 68%–99% in four out of four donors, whereas the
p110d-selective inhibitor IC reduced it to a lesser extent (47%–
68%) in three out of four donors. T cells of one donor (donor D)
exhibited low basal alloresponses to two independent stimulator
HCs. LY, but not IC, further reduced these responses. We then
sorted naive (CD3+CD25CD45RA+CD45ROCCR7+) and me-
mory (CD3+CD25CCR7 and CD3+CD25CD45RACD45RO+
CCR7+) human T cells to test whether p110d inactivation had a
differential impact on alloresponses in the two subsets (Fig-
ure 5B). The results showed that naive T cells and memory
T cells proliferated similarly after allostimulation and that allor-
eactivity of both subsets was inhibited upon p110d inactivation
with IC. This result contrasts with what we found in mouse
T cell subsets. However, similarly to what we found in mouse
T cell subsets, human naive T cells displayed a more marked in-
hibition of GzmB expression upon p110d inactivation than mem-
ory T cells (Figure 5C). The results suggest that, despite the
interindividual variations, p110d does modulate allorecognition
of HCs in human T cells. The impact of p110d inactivation on hu-
man naive and memory T cell subsets is different in comparison
to mice in that both human subsets require functional p110d to
proliferate in response to allostimulation. However, the impact
on GzmB expression is comparable in both species in that naive
T cells are more affected in both human and mouse T cells.
DISCUSSION
The PI3K/mammalian target of rapamycin pathway is a prom-
ising pharmacological target to treat leukemia (Janes et al.,
2010). P110d is an attractive target because it is expressed
nearly exclusively by hematopoietic cells (both immune cells
and malignant cells), where it regulates selective functions
(Ghigo et al., 2010). We show here that p110d inactivation re-
duces proliferation and delays differentiation of naı¨ve, but not
memory, allogeneic T cells, leading to low GzmB expression. In-
hibition of allogeneic naive T cells reduces GvHD severity and
Figure 5. Inactivation of p110d Inhibits Allogeneic Human T Cell Activation
(A) Healthy donor PBMCs were labeled with CFSE and cocultured with stimulator cells, i.e., irradiated PBMCs from another healthy donor. Mixed lymphocyte
cultures at 1:1 ratio were set up in the presence of DMSOvehicle control, IC (10 mM), or LY (10 mM). After 6 days, proliferation of allogeneic T cells was quantified by
enumerating the % of CFSElow cells. The histogram graph represents five combinations of responding and stimulator cells from five individual healthy donors
whose identity is marked by a capital letter.
(B) A similar experiment was performed using sorted naive and memory T cells from four different donors as responder cells.
(C) Granzyme B expression (GMFI) was measured by flow cytometry in CD8+ allogeneic T cells at day 6 of the MLR assay. Histograms are representative of two
independent experiments.improves the outcome of allogeneic HSCT. More importantly,
p110d inactivation preserves GvL.
The nature of the antigens, the costimulatory signals, and the
type of antigen-presenting cells (APCs) involved in GvHD remain
to be defined in order to determine how p110d inactivation con-
tributes to decrease GvHD severity. Nevertheless, modulation of
proximal T cell receptor (TCR) signaling appears to be key to alle-
viate GvHD and preserve GvL. Indeed, PKCa and PKCq inactiva-
tion in T cells also dissociates GvHD fromGvL and preserves anti-
microbial immunity (Valenzuela et al., 2009; Haarberg et al., 2013).
Mouse studies reveal thatmemory T cells are only able tomediate
GvL and not GvHD, whereas naive T cells mediate both (Dutt
et al., 2011). Memory T cells that sustain GvHD can be generated
in vivo during GvHD, but these are postmitotic CD8+ T cells
derived from naive donor T cells (Zhang et al., 2005b, 2005a).
We cannot exclude that these cells contribute to GvHD in our
model. Indeed, we show that allogeneic naive T cells give rise to
memory/effector T cells during GvHD, whereas allogeneic mem-
ory T cells are unable to induce GvHD. Unlike memory T cells,
naive T cells need costimulation following the engagement of
the TCR/CD3 complex, and indeed blocking CD28 and ICOS re-
ducesGvHD (Taylor et al., 2005; Li et al., 2011, 2013). Importantly,
CD28 and ICOS are dispensable for GvL (Ohata et al., 2002; Hub-
bard et al., 2005). P110d signals downstream of CD28, which, in
turn, enhances TCR-mediated p110d activation (Garc¸on et al.,
2008). P110d is also downstream of the ICOS signaling pathway,
although a PI3K-independent pathway has also been described
(Li et al., 2013). We show also that phosphorylation of Akt S473
and Akt T308 is inhibited in naive T cells, whereas memory
T cells exhibit normal levels of phosphorylation. Blocking p110d
is emerging as an effective strategy to inhibit costimulatory signals
on allogeneic naive T cells in order to reduce GvHD. Akt activity
following alloactivation of memory T cells seems to be indepen-
dent of p110d signaling. Further studies are needed to decipher
the nature of the receptors and the exact signaling pathways
involved in alloreactivity of memory T cells.CeP110d inactivation inhibits allostimulation of naive T cells, re-
sulting in low levels of GzmB expression at day 5 postinjection.
This may contribute to reduce GvHD. Indeed, other studies
have shown a role for bothGzmBandperforin in CD8+ T cells dur-
ing GvHD in fully major histocompatibility complex (MHC)-mis-
matched transplantation (Graubert et al., 1997). GzmB/ mice
can mediate stronger GvL with high production of IFN-g (Bian
et al., 2013). IFN-g production is known to promote GvL (Yang
et al., 2011), and we show that allogeneic memory T cells gener-
ated in vitro produce more IFN-g than naive T cells, and IFN-g
production is further enhanced when p110d is inactivated. It will
be also interesting to study the impact of enhanced IFN-g pro-
duction on natural killer (NK) cells and macrophages. Like NK
and NKT cells, memory T cells store preformed GzmBmRNA, al-
lowing for quicker responses upon activation (Stetson et al.,
2003). Further studies will define if the inhibition is at the level of
gene expression or mRNA translation. In line with our results, a
recent report shows that T cells from p110d/ mice express
low GzmB when activated with anti-CD3ε but, in contrast to our
data, antitumor T cell responses were impaired (Putz et al.,
2012). One possible explanation for the discrepancy may be
routed in both the geneticmakeup and the nature of the tumor tis-
sue, allogeneic lymphoma in our case and syngeneic carcinoma
in the other. Altogether, these results show that p110d inactiva-
tion does not impair memory T cell functions during allogeneic re-
sponses and is fully compatible with GvL.
In addition, p110d also regulates T cell migration and is a key
factor for CD62L cleavage; therefore, its inactivation interferes
with T cell recirculation (Sinclair et al., 2008). Abortive allores-
ponses and different patterns of migration of memory T cells
have been proposed to explain their inability to induce GvHD
(Chen et al., 2007). Despite the very rapid onset of acute GvHD
precluding the possibility to assess T cell infiltration in target or-
gans in our model, our results confirm that p110d inactivation in-
terferes with T cell activation, proliferation, and differentiation
upon stimulation by allogeneic APCs and that p110d inactivationll Reports 10, 702–710, February 10, 2015 ª2015 The Authors 707
does not interfere with GvL responses. Donor T cells are also
important for the engraftment of donor HCs. Given that p110d
inactivation can impair T cell trafficking, engraftment and recon-
stitution may be less efficient. However, our data suggest this is
not the case in our model, given that engraftment and reconstitu-
tion were not impaired in surviving mice analyzed after 3 months.
P110d inactivation in human T cells does not result in the
dichotomy between alloresponses in naive and memory T cells
observed in mice, as both subsets are affected in humans while
only naive T cells are affected in mice. Although alloreactivity
was inhibited in both human subsets, the decrease in GzmB
expression was greater in naive T cells, comparably to mouse
T cells. Memory T cells from human healthy donors are not com-
parablewithmemory T cells frommice kept in pathogen-free con-
ditions, and thismight explain, at least in part, the different impact
of p110d inactivation on alloresponses of human and mouse
memory T cells. Moreover, the role of naive and memory T cells
in humans during GvHD and GvL is also less clear than in mice,
where a clear dichotomy exists and memory T cells do not cause
GVHD. Nevertheless, in vitro evidence suggests that most of the
leukemia-reactive and GvHD-inducer human T cells come from
the naive compartment. Memory T cells exhibit lower alloreactiv-
ity and poor antileukemia response but may transfer memory re-
sponses against pathogens to the recipient (Distler et al., 2011).
Indeed, recent studies focus ondepletingCD45RA+ T cells, which
include naive and late differentiated T cells, to reduce GvHD and
keep a memory response (Touzot et al., 2014; Chan et al., 2014;
Teschner et al., 2014). Additional work on human T cell subsets
will aim to assess the impact of p110d inactivation on antileuke-
mia response and memory responses to pathogens.
Our study is a proof of principle that inhibition of p110d can
favorably sway the balance between GvHD and GvL in a model
of a strong acute GvHD and a highly aggressive tumor during
fully MHC-mismatched hematopoietic cell transplantation. In
the clinic, most allogeneic HSCTs are performed in the haploi-
dentical settings, so future studies will evaluate the impact of
p110d inactivation in haploidentical mouse models to mimic
the situation in human patients.
We propose that p110d inactivation reduces GvHD severity by
decreasing allogeneic responses of naive T cells and by inter-
fering with allogeneic T cell recirculation. GvL neither depends
on p110d in naive nor in memory T cells. Indeed, p110d inactiva-
tion does not interfere with effector functions and allostimulation
of memory T cells.
Imatinib (Gleevec) has revolutionized the treatment of chronic
myeloid leukemia. BRAF inhibitors and anti-CTLA-4 and anti-
PD-1 monoclonal antibodies are changing the landscape of can-
cer treatments (Eagle and Trowsdale, 2007; Chapman et al.,
2011; Mellman et al., 2011; Wolchok et al., 2013; Hamid et al.,
2013). Our results suggest that p110d inhibitors could be added
to the pharmacological arsenal to improve the outcome of allo-
geneic HSCT for the treatment of leukemia.EXPERIMENTAL PROCEDURES
Mice
C57BL/6 (here referred to as B6) and BALB/c mice were purchased from
Charles River Laboratories. P110dD910A (C57BL/6) strain was previously708 Cell Reports 10, 702–710, February 10, 2015 ª2015 The Authorsdescribed (Okkenhaug et al., 2002). Female mice were used at 8–12 weeks
old. All mice were bred at the University of Cambridge Central Biomedical
Services under pathogen-free conditions and housed according to UK
Home Office guidelines. Animal studies have been reviewed and approved
by the UK Home Office.
Cell Line
A20 (BALB/c, H-2d, B cell lymphoma) cells, a gift of Prof. K. Smith, were main-
tained in RPMI-1640 medium with stable glutamine and supplemented with
penicillin/streptomycin (all PAA), 10% fetal bovine serum (Life Technologies),
and 50 mM b-mercaptoethanol (Sigma).
Flow Cytometry
Conjugated monoclonal antibodies (mAbs) anti-mouse CD45 (30-F11), CD3ε
(500A2 or 17A2), H-2Kb (AF6-88.5), H-2Kd (SF-1.1.1), CD62L (MEL-14), CD44
(IM7), CD25 (PC61), IFN-g (XMG1.2), CD16/32-Fc blocking (93), granzyme B
(GB11), FoxP3 (NRRF-30), P-Akt (Ser473) (D9E), and P-Akt (Thr308) (D25E6)
and mAbs anti-human CD3 (UCHT1), CD45RA (HI100), CD45RO (UCHL1),
CD25 (BC96), CCR7 (G043H7), CD8 (SK1), and human Fc blocking were pur-
chased from BioLegend, eBioscience, BD Biosciences, or Cell Signaling.
GranzymeB and FoxP3were stained using the FoxP3 staining buffer set (eBio-
science) according to themanufacturer’s instructions. P-Akt was stained using
the BD Phosflow Lyse/Fix buffer and Perm Buffer III following the BD Phosflow
staining protocol. As negative controls for P-Akt, cells were pretreated for
30 min with the pan-PI3K inhibitor LY294002 (Cayman Chemical) or with the
pan-Akt phosphorylation inhibitor MK-2206 (Selleckchem). DAPI (Life Technol-
ogies) or fixable viability dye eFluor 450 (eBioscience) was used to exclude
dead cells. Samples were acquired on a LSR Fortessa (BD Biosciences) using
FACS Diva (BD Biosciences) and analyzed using FlowJo (Tree Star).
GvHD and GvL
In GvHD experiments, lethally irradiated (2 3 4.5 Gy) BALB/c host mice were
intravenously injected with 5 3 106 TCD BMCs from B6 mice alone (control)
or along with purified T cells from WT, p110dWT/D910A, or p110dD910A mice.
Magnetic beads (CD3 Microbead kit, Pan T Cell Isolation kit II; Miltenyi Biotec)
were used to deplete T cells in BMCs and to purify donor T cells from spleens
(purity >90%). In experiments using sorted cells, naive T cells (CD3+
CD25CD62L+CD44lo) and memory T cells (CD3+CD25CD44hi) were sorted
using either a FACS Aria III or a FACS Aria Fusion (BD Biosciences) (purity
>99%). In GvL experiments, 5 3 104 A20 cells were injected additionally.
Mice were under antibiotic treatment (Baytril, Bayer) during the duration of
the experiment. The clinical score was established at the time of sacrifice
and based upon mouse weight loss (0–2), posture (0–2), activity (0–2), and
fur texture (0–2), with the maximum clinical score being 8. Mice were culled
before reaching 20% (Figure 1) or 25% (Figures 2 and 4) of weight loss depend-
ing on the protocol and according to UK Home Office-regulated procedures.
Allogeneic T Cells and BMDCs Coculture
Lipopolysaccharide (LPS)-matured BMDCs were generated as previously
described (Lutz et al., 1999), then irradiated (21 Gy). Naive T cells and memory
T cells were fluorescence-activated cell sorted, labeled with 5 mM of carboxy-
fluorescein succinimidyl ester (CFSE, Life Technologies), and cocultured with
BMDCs (1:1 ratio) for 5 days in the presence of DMSO (Sigma-Aldrich), the
p110d-specific inhibitors IC87114 (UCB Cell Tech) and idelalisib (Selleck-
chem), or the pan-PI3K inhibitor LY294002 at the indicated doses. Then,
T cell proliferation (CFSE dilution) was assessed by flow cytometry. Generation
of alloreactive T cells was based on a previously described protocol (Sauer
et al., 2004). In brief, naive and memory T cells were primed with irradiated
(21 Gy) BALB/c BMDCs pulsed with A20 lysate, obtained by four freeze-
thaw cycles, at a 20:1 ratio for 5 days. T cells were expanded 2 days further
with plate-bound anti-CD3 antibody (clone 145-2C11) at 10 mg/ml, soluble
anti-CD28 (37.51) at 2 mg/ml, rhIL-2 (Proleukin, Novartis) at 20 IU/ml, and
rmIL-7 (Peprotech) at 4 ng/ml, then maintained in culture with cytokines only.
Human Cells and MLR Assay
PBMCs from healthy donors were isolated using a Histopaque-1077 gradient
(Sigma). Total PBMCs or sorted naive and memory T cells from a donor were
labeled with 5 mM of CFSE, mixed with irradiated (30 Gy) PBMCs from another
donor (1:1 ratio), cultured for 6 days in the presence of DMSO or PI3K inhibi-
tors, and analyzed by flow cytometry.
Statistical Analysis
A two-tailed, unpaired Student’s t test (Excel, Microsoft), Mantel-Cox test, or
one-way ANOVA followed by Tukey’s multiple comparisons test (GraphPad
Prism 6) was used to statistically analyze the data, where p < 0.05 was consid-
ered significant. All data are expressed as means ± range.
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